ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "chemokines"

  • Abstract Number: 0013 • ACR Convergence 2022

    Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome

    Eon Jeong Nam1, Na Ri Kim1 and Gun Woo Kim2, 1Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, 2Daegu Fatima Hospital, Daegu, Republic of Korea

    Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder with lymphocytic infiltration in exocrine and non-exocrine epithelia, in which epithelial cells play a critical role…
  • Abstract Number: 0266 • ACR Convergence 2022

    Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression

    Judith Heutz1, Cleo Rogier2, Ellis Niemantsverdriet3, Susan van den Eeden4, Pascal de Jong5, Annemieke Geluk6 and Annette van der Helm-van Mil7, 1Erasmus Medical Center, Rotterdam, Netherlands, 2Erasmus MC, Rotterdam, Netherlands, 3LUMC, Leiden, Netherlands, 4Leiden University Medical Center (LUMC), Leiden, Netherlands, 5ErasmusMC, Hendrik Ido Ambacht, Netherlands, 6Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, 7Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine…
  • Abstract Number: 0586 • ACR Convergence 2022

    Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse

    Shuzo Sato1, Xian Zhang2, Naoki Matsuoka1, Yuya Sumichika1, Kenji Saito1, Shuhei Yoshida1, Haruki Matsumoto1, Jumpei Temmoku1, Yuya Fujita1, Tomoyuki Asano1, Hiroshi Watanabe1 and Kiyoshi Migita1, 1Fukushima Medical University, Fukushima, Japan, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Friend leukemia virus integration 1 (Fli-1) belongs to the Ets family of transcription factors and plays an important role in the development of lupus…
  • Abstract Number: 0614 • ACR Convergence 2022

    Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

    nozima Aripova1, Michael Duryee1, carlos hunter1, Eric Daubach1, Evan Ryan1, Geoffrey Thiele1 and Ted Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Cellular interactions between synovial macrophages and human fibroblast-like synoviocytes (HFLS) contribute to articular inflammation and fibrosis in rheumatoid arthritis (RA), leading to subsequent joint…
  • Abstract Number: 0655 • ACR Convergence 2022

    Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

    Alessandra Ida Celia1, Jeffery Hodgin2, Avi Rosenberg3, Laurence S Magder4, Jill Buyon5, Betty Diamond6, Judith James7, William Apruzzese8, Paride Fenaroli9, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter izmirly10, Michael Belmont5, Anne Davidson6, Daniel W. Goldman11, the Accelerating Medicines Partnership (AMP) RA/SLE12, Michelle Petri11 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2University of Michigan, Ann Arbor, MI, 3Johns Hopkins University, Ballwin, MO, 4University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Brigham and Women's Hospital, Boston, MA, 9Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, 10NYU Long Island School of Medicine, New York, NY, 11Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 12Multiple Insitutions

    Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
  • Abstract Number: 1165 • ACR Convergence 2022

    Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis

    Marie Beaufrère1, Manon Jacoutot1, Amel Ait Ali Said1, Roula Said-Nahal2, Gina Cosentino3, Chiara Rizzo3, Maxime Breban4 and Simon Glatigny4, 1Paris Saclay University / INSERM 1173, Montigny-le-Bretonneux, France, 2Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, 3INSERM 1173, Montigny-le-Bretonneux, France, 41INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France

    Background/Purpose: Spondylarthritis (SpA) is a group of chronic inflammatory disorders with osteoarticular and extraarticular symptoms, including colitis, highly associated with the human leukocyte antigen (HLA)…
  • Abstract Number: 1554 • ACR Convergence 2022

    Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis

    Cameron Rankin1, Peter Grayson2, Bates Gribbons3, Kaitlin Quinn4, Christopher Redmond5 and Wanxia Tsai1, 1NIAMS/NIH, Bethesda, MD, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3McGovern Medical School, Colleyville, TX, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 5National Institutes of Health, Rockville, MD

    Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…
  • Abstract Number: 1682 • ACR Convergence 2022

    Peptidyl Arginine Deiminase Expression and Macrophage Polarization Following Stimulation with Citrullinated and Malondialdehyde-acetaldehyde Modified Fibrinogen

    nozima Aripova1, Michael Duryee1, carlos hunter1, Bryant England1, Debra Romberger1, James O'Dell1, Geoffrey Thiele1 and Ted Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Post-translational modifications (PTM) of extracellular matrix proteins, such as fibrinogen, have been implicated in the pathogenesis of rheumatoid arthritis (RA). Citrullination, a type of…
  • Abstract Number: 0514 • ACR Convergence 2021

    Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel1, Anil singh1, Judy Vinh1, H. Mark Kenney2, Edward Schwarz3, David Fox4, Sadik Khuder5 and Salah-uddin Ahmed1, 1Washington State University, Spokane, WA, 2University of Rochester Medical Center, Rochester, NY, 3University of Rochester, Rochester, NY, 4Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 5Department of Medicine and Public Health, University of Toledo,, Toledo, OH

    Background/Purpose: TNF-α drives RA synovial fibroblast (RASF)-mediated hyperplasia and joint tissue destruction. Extracellular sulfatase-2 (Sulf-2) influences receptor/ligand binding and subsequent signaling of chemokines, cytokines, and…
  • Abstract Number: 0515 • ACR Convergence 2021

    The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
  • Abstract Number: 1365 • ACR Convergence 2021

    Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis

    Isabella Atzeni1, Yehya Al-Adwi2, Berber Doornbos-van der Meer2, Amel Eman Abdulle2, Anniek Van Roon2, Alja J. Stel2, Harry Van Goor2, Andries Smit2, Johanna Westra2 and Douwe J Mulder2, 1University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, 2University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

    Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…
  • Abstract Number: 1381 • ACR Convergence 2021

    Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis

    Imon Barua1, Håvard Fretheim2, Hilde Jenssen Bjørkekjær3, Henriette Didriksen4, Oyvind Midtvedt2, Trond Mogens AAløkken2, Torhild Garen5, Oyvind Molberg6, John Belperio7 and Anna-Maria Hoffmann-Vold1, 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, 4Oslo University Hospital, Moss, Norway, 5Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, 6Oslo University Hospital, Oslo, Nepal, 7University of California Los Angeles Interstitial Lung Disease Center, Los Angeles, CA

    Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…
  • Abstract Number: 1440 • ACR Convergence 2021

    Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome

    Sara McCoy, Ilya Gurevic, Maxwell Parker and Jacques Galipeau, University of Wisconsin, Madison, WI

    Background/Purpose: Sjӧgren’s syndrome (SS) is a systemic autoimmune disease that is associated with a lymphoma risk 14-fold that of the general population. Greater focal lymphocytic…
  • Abstract Number: 1767 • ACR Convergence 2021

    CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation

    Xiubo Fan1, Chin Teck Ng1, Dianyang Guo1, Frances Lim1, Annie Law2, Julian Thumboo1, William Hwang3 and Andrea Low1, 1Singapore General Hospital, Singapore, Singapore, 2Singhealth, Singapore, Singapore, 3National Cancer Centre Singapore, Singapore, Singapore

    Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease characterized by dysregulation of both innate and adaptive immunity. Current therapeutic options are limited,…
  • Abstract Number: 1837 • ACR Convergence 2021

    KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD

    Yu-Hsiang Chiu1, Mareye Voortman1, Eveline Delemarre1, Stefan Nierkens1, Pim de Jong1, Firdaus Mohamed Hoesein1, Jan Grutters2, Jacob van Laar1 and Julia Spierings3, 1University Medical Centre Utrecht, Utrecht, Netherlands, 2St. Antonius Hospital, Nieuwegein, Netherlands, 3University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology